Zhiyan Consulting released the "Market Research Report on China's Ankylosing Spondylitis Treatment Drug Industry"

The "2024-2030 China Ankylosing Spondylitis Treatment Drug Industry Market Operation Pattern and Strategic Consulting Research Report" (hereinafter referred to as the "Report") carefully compiled by the Zhiyan Consulting expert team was released, which aims to analyze the future market trend of the ankylosing spondylitis treatment drug industry, tap the development potential of the ankylosing spondylitis treatment drug industry, and predict the development prospects of the ankylosing spondylitis treatment drug industry from the perspective of the national economic and industrial development strategy. Contribute to the high-quality development of the ankylosing spondylitis treatment drug industry.

This report systematically and objectively analyzes the development and operation of the mainland ankylosing spondylitis treatment drug industry from the perspectives of the development environment, global development trend, industry scale, competition pattern, and key enterprises of the national ankylosing spondylitis treatment drug industry in 2023, and looks forward to the development trend of China's ankylosing spondylitis treatment drug industry in 2024. The report is a work that systematically analyzes the development of China's ankylosing spondylitis treatment drug industry in 2023, which has important reference value for a comprehensive understanding of the development of China's ankylosing spondylitis treatment drug industry and academic research and practice related to the development of the ankylosing spondylitis treatment drug industry.

Ankylosing spondylitis (AS) is a disease in which inflammation of the sacroiliac joints and spinal entheses is the main symptom. It is a chronic inflammatory disease characterized by fibrosis and ossification of the fibrous tissues of the fibrous ring of the intervertebral disc and its vicinity, as well as joint rigidity. Ankylosing spondylitis is a chronic disease with the spine as the main lesion, involving the sacroiliac joints, causing ankylosis and fibrosis of the spine, causing different degrees of eye, lung, muscle and bone lesions, and is an autoimmune disease. Ankylosing spondylitis treatment drugs include biologics, chemical drugs, and others. In clinical practice, drugs for lesions of affected organs are often used in combination with the treatment of AS at different times. Because the disease is prone to invade multiple tissues and organs of the human body, the medication of AS patients can be divided into therapeutic drugs for the disease itself, and adjuvant drugs for other affected organs and tissues. Among them, the therapeutic drugs include non-steroidal anti-inflammatory drugs, anti-rheumatic disease modifiers and glucocorticoids and other chemical drugs, traditional Chinese medicine and biological agents, and adjuvant treatment drugs can be divided into prophylactic drugs and drugs for affected system lesions, preventive drugs include gastrointestinal drugs and osteoporosis drugs, drugs for lesions of affected organs, and drugs for eyes, skin and other parts.

Although some biological drugs have been included in the medical insurance to reduce the price to a certain extent and can be reimbursed, the price is still relatively high compared with chemical drugs, and the use is relatively small. However, due to the excellent treatment effect, the ability of residents to pay has improved, and the penetration rate of biological drugs has also grown steadily, and in terms of the scale of subdivisions, the treatment drugs for ankylosing spondylitis in mainland China are mainly chemical drugs and others, with a market size of about 10.332 billion yuan in 2022. In terms of overall subdivision, the proportion of auxiliary drugs is slightly higher than that of therapeutic drugs, and the scale of drugs for prophylactic and affected system lesions will be 6.759 billion yuan in 2022.

From the relatively large number of domestic ankylosing spondylitis treatment drugs, the large number of domestic production enterprises, and the relatively fierce market competition, the more well-known domestic ankylosing spondylitis treatment drugs mainly include TNF-α inhibitors such as Yisaipu, Ambronic, and Qiangke, as well as menofine (aceclofenac tablets), Su Libao (celecoxib capsules), Easy Bird (loxoprofen sodium capsules) and other brands. The production capacity of domestic enterprises has generally increased steadily, the number of approvals has increased rapidly, the clinical trials and indications of some products have been accelerated, and domestic brands have gradually become the main players in ankylosing spondylitis treatment drugs, and their market share has continued to increase, but there is still a significant gap with leading foreign companies in terms of innovative drugs.

Due to its unique mechanism of action and significant efficacy, biologics are increasingly used in the treatment of ankylosing spondylitis. By acting on specific immune molecules and cells, biologics are able to inhibit the inflammatory process more effectively, thereby reducing pain and improving joint function in patients. Compared with traditional non-steroidal anti-inflammatory drugs and anti-rheumatic drugs, biologics have higher targeting and lower incidence of side effects, and the proportion of biologics in the market for ankylosing spondylitis treatment drugs is expected to gradually increase in the future.

With the continuous expansion of the market for ankylosing spondylitis treatment drugs and the continuous emergence of new drugs such as biologics, the market competition is becoming increasingly fierce. Many domestic and foreign pharmaceutical companies have invested heavily in the research and development and marketing of new drugs, striving to occupy a larger share of the market. At the same time, with the continuous strengthening of the country's supervision of the pharmaceutical industry and the continuous adjustment of medical insurance policies, market competition will be more standardized and transparent. Pharmaceutical companies need to continuously strengthen their R&D strength and market competitiveness in order to remain invincible in the fierce market competition.

The "2024-2030 China Ankylosing Spondylitis Treatment Drug Industry Market Operation Pattern and Strategic Consulting Research Report" is an important achievement of Zhiyan Consulting, a powerful embodiment of Zhiyan Consulting's leading industry reform, affection for the industry, and implementation of its mission, and an indispensable tool for practitioners in the field of ankylosing spondylitis treatment drugs to take the pulse of the industry. Zhiyan Consulting has formed a complete and three-dimensional think tank system, serving the government, enterprises, financial institutions, etc., for many years, providing science and technology, consulting, education, ecology, capital and other services.

Data Description:

1. The core data of this report is updated to December 2023, mainly based on Chinese mainland data, and a small amount involves global and related regional data; The forecast period covers the period from 2024 to 2030, and the data content involves the output value, market size and segment size of the ankylosing spondylitis treatment drug industry.

2. In addition to first-hand research information and data, authoritative data sources such as the National Bureau of Statistics, China Customs, industry associations, and public reports of listed companies (prospectuses, transfer prospectuses, annual reports, inquiry reports, etc.) also constitute the data sources of this report. The first-hand data comes from the first-hand information data obtained by the research team from interviews with key enterprises in the industry, and the main interview subjects include corporate executives, industry experts, technical leaders, downstream customers, distributors, agents, distributors and upstream raw material suppliers. Secondary sources mainly include relevant industry news, company annual reports, non-profit organizations, industry associations, government agencies and third-party databases from around the world.

3. The core data of the report is based on the company's strict data collection, screening, processing, analysis system and independent calculation model to ensure the accuracy and reliability of statistical data.

4. The data used in this report are all from compliance channels, and the analysis logic is based on the professional understanding of the Zhiyan team, which clearly and accurately reflects the research views of analysts.

Table of Contents:

Chapter 1 Overview of the development of China's ankylosing spondylitis treatment drug industry in 2023

Section 1 Definition and Classification of Ankylosing Spondylitis Treatment Drugs Industry

1. Definition and classification of ankylosing spondylitis treatment drug industry

2. The main business model of the ankylosing spondylitis treatment drug industry

3. Analysis of the characteristics of the ankylosing spondylitis treatment drug industry

Section 2 Analysis of the political and legal environment of the ankylosing spondylitis treatment drug industry

1. Analysis of industry management system

Second, the main laws and regulations of the industry

Third, the relevant development plan of the industry

Section 3 Analysis of the Economic Environment of the Ankylosing Spondylitis Treatment Drug Industry

1. Analysis of the global macroeconomic situation

2. Analysis of the domestic macroeconomic situation

3. Analysis of the macroeconomic environment of the industry

Section 4 Analysis of the technical environment of the ankylosing spondylitis treatment drug industry

1. The development level of drug technology for the treatment of ankylosing spondylitis

Second, the main technical status and development trend of the industry

Chapter 2 Development status and experience of the global ankylosing spondylitis treatment drug industry in 2023

Section 1 Overview of the development of the global ankylosing spondylitis treatment drug industry

1. Market size analysis of the global ankylosing spondylitis treatment drug industry

2. Analysis of the market structure of the global ankylosing spondylitis treatment drug industry

3. Analysis of the competitive landscape of the global ankylosing spondylitis treatment drug industry

Section 2 Analysis of the development of major foreign ankylosing spondylitis treatment drugs

1. Analysis of the development status of the drug industry for the treatment of ankylosing spondylitis in the European Union

2. Analysis of the development status of the drug industry for the treatment of ankylosing spondylitis in the United States

3. Analysis of the development status of the drug industry for the treatment of ankylosing spondylitis in Japan

Section 3 2024-2030 Global Ankylosing Spondylitis Treatment Drug Industry Development Prospect Forecast

Chapter 3 Analysis of the development trend of China's ankylosing spondylitis treatment drug industry in 2023

Section 1 Development status of China's ankylosing spondylitis treatment drug industry in 2023

1. The development status of the brand in the ankylosing spondylitis treatment drug industry

2. The current situation of the consumer market of the ankylosing spondylitis treatment drug industry

3. Hierarchical analysis of market demand for drugs for the treatment of ankylosing spondylitis

4. Analysis of the market trend of drugs for the treatment of ankylosing spondylitis in China

Section 2 Development of drug industry for the treatment of ankylosing spondylitis in China

1. Review of the development of China's ankylosing spondylitis treatment drug industry in 2023

2. Analysis of the development of China's ankylosing spondylitis treatment drug industry in 2023

3. Analysis of the characteristics of China's ankylosing spondylitis treatment drug market in 2023

Section 3 Supply and demand analysis of China's ankylosing spondylitis treatment drug industry

1. Analysis of the total supply of drugs for the treatment of ankylosing spondylitis in China in 2023

2. Analysis of the market demand structure of drugs for the treatment of ankylosing spondylitis in China in 2023

Chapter 4 China Ankylosing Spondylitis Treatment Drugs Industry Competition Situation and Strategies in 2023

Section 1 Analysis of the overall market competition in the industry

1. Analysis of the competitive structure of the ankylosing spondylitis treatment drug industry

1. Competition between existing enterprises

2. Analysis of potential entrants

3. Threat analysis of substitutes

4. Bargaining power of suppliers

5. Customer bargaining power

6. Summary of the characteristics of the competitive structure

2. Analysis of the competition pattern among enterprises in the ankylosing spondylitis treatment drug industry

Section 2 Overview of the competitive landscape of China's ankylosing spondylitis treatment drug industry

1. Competition in the ankylosing spondylitis treatment drug industry

2. Analysis of the competitiveness of China's ankylosing spondylitis treatment drug industry

1. Analysis of the competitiveness of China's ankylosing spondylitis treatment drug industry

2. The advantages of market competition among Chinese ankylosing spondylitis treatment drug companies

3. Ways to improve the competitiveness of domestic ankylosing spondylitis treatment drug companies

3. Analysis of competitive strategies in the China Ankylosing Spondylitis Treatment Drug Market from 2024 to 2030

Chapter 5 Analysis of the development status and trends of seven regions of China's ankylosing spondylitis treatment drugs or industries in 2023

Section 1 Analysis and Forecast of Ankylosing Spondylitis Treatment Drug Industry in North China